GlassScriptPhysician profile
Ross Miller
NPI 1134209794
$64,968.47
in general payments reported to CMS, 2019-2025
30 companies · $5,782 in 2025
The $5,782 reported for 2025 was more than what 92% of Public Health & General Preventive Medicine providers received nationally (typical 2025 total: $95.27).
See the full distribution for Public Health & General Preventive Medicine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $4,447 · 2021: $15K · 2022: $5,653 · 2023: $11K · 2024: $10K · 2025: $5,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $5,174 · Honoraria: $1,500 · Food and Beverage: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,110.00 |
| Travel and Lodging | $5,173.80 |
| Honoraria | $1,500.00 |
| Food and Beverage | $1,166.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $10,527.95 | 2020-2022 | |
| Novo Nordisk INC | $8,018.10 | 2019-2023 | |
| Gilead Sciences, INC. | $7,400.00 | 2019 | |
| Boehringer Ingelheim International Gmbh | $6,250.03 | 2024 | |
| Gen-Probe, INC. | $5,761.11 | 2024-2025 | Aptima, None |
| Vertex Pharmaceuticals Incorporated | $5,200.00 | 2021 | |
| Alkermes, INC. | $5,061.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,941.71 | 2020-2025 | |
| Biogen, INC. | $3,710.00 | 2021-2022 | |
| Shield Therapeutics INC | $3,193.50 | 2023 | Accrufer |
| Genentech USA, INC. | $1,575.00 | 2020 | |
| Urovant Sciences INC | $1,046.94 | 2021-2022 | |
| Hologic Sales and Service, LLC | $541.95 | 2024 | Btx, Aptima |
| Dr.Reddy'S Laboratories,INC. | $350.00 | 2023 | Hydroxychloroquine Sulfate |
| Sanofi-Aventis U.S. LLC | $303.17 | 2020-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $232.61 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $155.78 | 2019-2021 | |
| Boston Scientific Corporation | $141.84 | 2024 | Apollo Esg Nxt System |
| Neurocrine Biosciences, INC. | $81.11 | 2022 | |
| Genzyme Corporation | $80.94 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $73.61 | 2023-2024 | Myfembree, Gemtesa |
| Aerie Pharmaceuticals, INC. | $57.58 | 2019 | |
| Glaxosmithkline, LLC. | $47.13 | 2020 | |
| Mdd US Operations, LLC | $44.79 | 2019 | |
| Verrica Pharmaceuticals INC. | $41.04 | 2024 | Ycanth |
| Cmp Pharma, INC. | $31.92 | 2023 | Norliqva |
| Lilly USA, LLC | $30.46 | 2020 | |
| Heartflow, INC. | $29.55 | 2022 | |
| Smith+Nephew, INC. | $25.07 | 2019 | |
| USA Angelalign Technology Corp | $14.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.